MedDRA preferred term

Pallor: adverse event reports recording this term

26,822 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

26,822
reports recording the term: 0.1% of all reports; 1,151
reports, 12 months to June 2026: 1,307 in the 12 months before; 76.4%
marked serious by the reporter: 57.4% across all reports; 7.4%
record death among outcomes, as reported: 9.1% across all reports

26,822 reports in FDA's adverse event database record the MedDRA term "Pallor": 0.1% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

1,151 reports recorded it in the 12 months to June 2026, down 12% from 1,307 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 76.4% are marked serious, 7.4% include death among the outcomes and 40.3% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Anticoagulant Sodium Citrate, Humira and Remicade. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Anticoagulant Sodium Citrate	Anti-coagulant	2,657	39.2%
Humira	—	565	0.1%
Remicade	Tumor necrosis factor blocker	485	0.3%
Enbrel	Tumor necrosis factor blocker	387	0.1%
Aspirin	Nonsteroidal anti-inflammatory drug	329	0.5%
Clopidogrel	P2Y12 platelet inhibitor	299	1%
Inflectra	Tumor necrosis factor blocker	255	1%
Methotrexate	Folate analog metabolic inhibitor	246	0.1%
Infliximab	Tumor necrosis factor blocker	229	0.4%
Ibuprofen	Nonsteroidal anti-inflammatory drug	227	0.3%
Acetylsalicylic Acid	—	215	0.9%
Rituximab	CD20-directed cytolytic antibody	185	0.1%
Vedolizumab	Integrin receptor antagonist	184	0.3%
Xarelto	Factor Xa inhibitor	183	0.1%
Apixaban	Factor Xa inhibitor	167	0.4%
Carboplatin	Platinum-based drug	167	0.2%
Acetaminophen	Nonsteroidal anti-inflammatory drug	165	0.2%
Prednisolone	Corticosteroid	164	0.2%
Oxaliplatin	Platinum-based drug	162	0.3%
Soliris	Complement inhibitor	157	0.3%
Omeprazole	Proton pump inhibitor	155	0.3%
Sandostatin LAR Depot	—	153	0.9%
Cyclophosphamide	Alkylating drug	152	0.1%
Remodulin	Prostacycline vasodilator	146	0.3%
Lorazepam	Benzodiazepine	142	0.4%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Anti-coagulant	2,715	9.4%	0.1%
Tumor necrosis factor blocker	1,482	0.1%	0.1%
Nonsteroidal anti-inflammatory drug	1,175	0.2%	0%
Kinase inhibitor	746	0.1%	0%
Atypical antipsychotic	723	0.1%	0%
Corticosteroid	712	0.1%	0%
Factor Xa inhibitor	587	0.2%	0.2%
Opioid agonist	552	0.1%	0%
Serotonin reuptake inhibitor	503	0.2%	0.1%
Benzodiazepine	494	0.2%	0.1%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 22.3%621

2 to 115.1%1,364

12 to 173.8%1,016

18 to 4424.3%6,508

45 to 6420.8%5,567

65 to 7411.4%3,045

75 and over11.1%2,974

Age not given21.4%5,727

Patient sex

Female52.1%13,980

Male41%11,010

Not given6.8%1,832

Grey bar: all 20,646,523 reports in the database. 44% of these reports give the United States as the country.

Questions about "Pallor"

What does "Pallor" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record pallor?

26,822 reports through June 2026 (0.1% of all reports), 1,151 of them in the latest 12 months.

Which drugs appear most often in these reports?

Anticoagulant Sodium Citrate (2,657), Humira (565), Remicade (485), Enbrel (387) and Aspirin (329). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.